Antibiogram of multidrug resistant Acinetobacter baumannii isolated from clinical specimens at King Hussein Medical Centre, Jordan: A retrospective analysis;Antibiogramme d’isolats d’Acinetobacter baumannii multirésistants à partir de différents échantillons cliniques au Centre médical Roi Hussein en Jordanie: Une analyse rétrospective

Eastern Mediterranean Health Journal

Volumn 21, Issue 11, 2015, Pages 828-834

  Batarseh, A ^a   Al Sarhan, A ^a   Maayteh, M ^a   Al Khatirei, S ^a   Alarmouti, M ^a  

^a KING HUSSEIN MEDICAL CENTER   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MINOCYCLINE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TETRACYCLINE; TICARCILLIN; TIGECYCLINE; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC SENSITIVITY; ARTICLE; FEMALE; HUMAN; JORDAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVALENCE; RETROSPECTIVE STUDY; ACINETOBACTER INFECTIONS; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; EPIDEMIOLOGY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; HUMANS; JORDAN; MICROBIAL SENSITIVITY TESTS; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 84961680138     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: 10.26719/2015.21.11.828     Document Type: Article

References (33)

1. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008 Apr 15;46(8):1254-63. PMID:18444865.
2. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006 Mar 1;42(5):692-9. PMID:16447117.
3. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008 Jul;21(3):538-82. PMID:18625687.
4. Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care. 2011;1:47. 10.1186/2110-5820-1-47 PMID:22112929.
5. Dhabaan GN, Hamimah H, Shorman MA. Emergence of extensive drug-resistant Acinetobacter baumannii in North of Jordan. Afr J Microbiol Res. 2011;5(9):1070-4.
6. Abu Setteh MH. Antibiotic resistance patterns of Acinetobacter species isolated in King Hussein Medical Center, Jordan. Saudi Med J. 2005 Jan;26(1):153-5. PMID:15756380.
7. Al-Dabaibah N, Obeidat NM, Shehabi AA. Epidemiology features of Acinetobacter baumannii colonizing respiratory tracts of ICU patients. International Arabic Journal of Antimicrobial Agents. 2012;2(2).
8. Performance standards for antimicrobial susceptibility testing. 22nd informational supplement, M100-S22. Wayne (PA): Clinical and Laboratory Standards Institute; 2012.
9. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol. 2006 Dec;55(Pt 12):1619-29. PMID:17108263.
10. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis. 2008 Apr 1;46(7):1121-2, author reply 1122. PMID:18444833.
11. Brink AJ, Bizos D, Boffard KD, Feldman C, Grolman DC, Pretorius J, et al.; Association of Surgeons of South Africa; Critical Care Society of Southern Africa; Federation of Infectious Diseases Societies of Southern Africa; South African Thoracic Society; Trauma Society of South Africa. Guideline: appropriate use of tigecycline. S Afr Med J. 2010 Jun;100(6 Pt 2):388-94. PMID:20529440.
12. Wilson SJ, Knipe CJ, Zieger MJ, Gabehart KM, Goodman JE, Volk HM, et al. Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital. Am J Infect Control. 2004 Oct;32(6):342-4. PMID:15454892.
13. Fierobe L, Lucet JC, Decré D, Muller-Serieys C, Deleuze A, Joly-Guillou ML, et al. An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients. Infect Control Hosp Epidemiol. 2001 Jan;22(1):35-40. PMID:11198020.
14. Bayuga S, Zeana C, Sahni J, Della-Latta P, el-Sadr W, Larson E. Prevalence and antimicrobial patterns of Acinetobacter baumannii on hands and nares of hospital personnel and patients: the iceberg phenomenon again. Heart Lung. 2002 Sep-Oct;31(5):382-90. PMID:12487017.
15. Japoni-Nejad A, Sofian M, van Belkum A, Ghaznavi-Rad E. Nosocomial outbreak of extensively and pandrug-resistant Acinetobacter baumannii in tertiary hospital in central part of Iran. Jundishapur J Microbiol. 2013;6(8):1-5.
16. Bacakoğlu F, Korkmaz Ekren P, Taşbakan MS, Başarik B, Pullukçu H, Aydemir S, et al. Solunumsal yogun bakim unitesinde coklu antibiyotik direncli Acinetobacter baumannii enfeksiyonu. [Multidrug-resistant Acinetobacter baumannii infection in respiratory intensive care unit]. Mikrobiyol Bul. 2009 Oct;43(4):575-85. PMID:20084910.
17. Davood Y, Shahram A, Latif G, et al. Prevalence and drug resis tance of Acinetobacter baumannii in ICU of a teaching hospital. J. Appl. Environ. Biol. Sci. 2013;3(9):22-7.
18. Jaggi N, Sissodia P, Sharma L. Acinetobacter baumannii isolates in a tertiary care hospital: antimicrobial resistance and clinical significance. J Microbiol Infect Dis. 2012;2(2):57-63.
19. Alessandro C, Silvia D, Paolo V, et al. In vitro activity of tige cycline against multidrug resistant Acinetobacter baumanniiJ. Antimicrob Chemother. 2008;62(2):422-42.
20. Sivaranjani V, Umadevi S, Srirangaraj S, Kali A, Seetha K. Multidrug resistant Acinetobacter species from various clinical samples in a tertiary care hospital from South India. Australas Med J. 2013;6(12):697-700. PMID:24391681.
21. Soo-Sum L, Zarizal S, Salwani I, Rahman NIA, Othman N, Abdullah FH, et al. Prevalence and genetic characterization of polymyxin-resistant Acinetobacter baumannii isolated from a tertiary hospital in Terengganu, Malaysia. ISRN Microbiol. 2014 Mar 19;2014:953417 PMID:25006521.
22. Rahbar M, Mehrgan H, Aliakbari NH. Prevalence of antibioticresistant Acinetobacter baumannii in a 1000-bed tertiary care hospital in Tehran, Iran. Indian J Pathol Microbiol. 2010 Apr-Jun;53(2):290-3. PMID:20551535.
23. Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother. 2012 Jul;67(7):1607-15. PMID:22441575.
24. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis. 2005 May 1;40(9):1333-41. PMID:15825037.
25. Casal M, Rodríguez F, Johnson B, Garduno E, Tubau F, de Lejarazu RO, et al. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-nonsusceptible Acinetobacter. J Antimicrob Chemother. 2009 Jul;64(1):69-72. PMID:19451133.
26. BSAC methods for antimicrobial susceptibility testing, version 12 May 2013 [Internet]. Birmingham: British Society for Antimicrobial Chemotherapy; 2013 (http://www.bsac.org. uk/wp-content/uploads/2012/02/Version-12-Apr-2013_final. pdf, accessed 13 August 2105).
27. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother. 2008 Jul;62(1):45-55. PMID:18436554.
28. Arroyo LA, Mateos I, González V, Aznar J. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi-and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother. 2009 Mar;53(3):1295-6. PMID:19075049.
29. Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother. 2007 Nov;60(5):1163-7. PMID:17761499.
30. Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis. 2005;5:24. PMID:15819983.
31. Valencia R, Arroyo LA, Conde M, Aldana JM, Torres MJ, Fernández-Cuenca F, et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol. 2009 Mar;30(3):257-63. PMID:19199531.
32. Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis. 2005 Jan;11(1):22-9. PMID:15705318.
33. Tan TY, Ng LS, Tan E, Huang G. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother. 2007 Aug;60(2):421-3. PMID:17540671.